{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:28:24Z","timestamp":1776162504372,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T00:00:00Z","timestamp":1134345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2006,2]]},"abstract":"Abstract<\/jats:title>Aims<\/jats:title>Correct execution of prescribed dosing regimen(s) is essential for patients to benefit from lipid lowering treatments. The objective of this study was to estimate the effect of a pharmaceutical care program on the adherence of once\u2010daily atorvastatin treatment in patients with elevated cholesterol levels.<\/jats:p><\/jats:sec>Methods<\/jats:title>In both linguistic regions of Belgium, two districts were randomized between usual care and a supportive intervention program. Eligible patients included hyperlipemic subjects taking atorvastatin for at least 3 months. \u2018Adherence\u2019 was defined as the proportion of days during which the electronic device record showed that the patient had taken the daily dose. \u2018Persistence\u2019 quantifies how long the treatment is executed.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 392 patients from 35 pharmacies were included in the intent\u2010to\u2010treat (ITT) analysis of the data (194 patients received intervention and 198 in the control group). The intervention resulted in a 6.5% increase in post\u2010baseline adherence (p<\/jats:italic>\u2009<\u20090.001) mainly driven by a 13% increase in persistence at 1 year (p<\/jats:italic>\u2009=\u20090.002).<\/jats:p><\/jats:sec>Conclusion<\/jats:title>A supportive pharmaceutical care program consisting of review by patient and pharmacist of each patient's electronically compiled dosing history, plus educational reminders, improves patient adherence to the once\u2010daily atorvastatin dosing regimen, mainly by extending persistence. Copyright \u00a9 2005 John Wiley & Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1198","type":"journal-article","created":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T11:53:05Z","timestamp":1134388385000},"page":"115-121","source":"Crossref","is-referenced-by-count":62,"title":["Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once\u2010daily atorvastatin"],"prefix":"10.1002","volume":"15","author":[{"given":"Bernard","family":"Vrijens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Belmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelijne","family":"Matthys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik de","family":"Klerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Lesaffre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,12]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"351","article-title":"Reduction in incidence of coronary heart disease; (II) The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","author":"The Lipid Research Clinics Coronary Primary Prevention Trial results: (I)","year":"1984","journal-title":"JAMA"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2000.36006.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.4.455"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"e_1_2_1_6_2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1998.1243"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03420220087032"},{"key":"e_1_2_1_9_2","unstructured":"VrijensB RingeJD WattsNB et al.Electronic monitoring of adherence therapy in postmenopausal osteoporosis: The IMPACT study. Osteoporosis International.14(Suppl. 7):S1\u2013S112."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(00)00088-X"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90160-0"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1198","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T12:39:40Z","timestamp":1700051980000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,12]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["10.1002\/pds.1198"],"URL":"https:\/\/doi.org\/10.1002\/pds.1198","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,12]]}}}